Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.
The power to stop cancer.
The experience to know how.
The dedication to make a difference.
Dual purpose enabling a targeted medicine approach
Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.
Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.
Approach
Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.
Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.
Novel targets for solid tumors
Largest gene family in humans
132 known protein/receptor pairs
>65 with increased tumor expression
Given GPCR overexpression in many tumors, they can be targeted in a vast range of cancer indications, from common to rare tumors.
Clinical trials
Study R8760-101 is a multi-center Phase 1 clinical trial evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma. 68Ga-R8760 was discovered by Radionetics Oncology for identifying melanocortin 2 receptor (MC2R)-expressing adrenocortical cancer lesions to select patients who may benefit from MC2R-directed radioconjugate therapy.
For additional information about the study, please see study NCT05999292
Meet
our team
Investors
Board
of
directors
Crinetics
Frazier Life Sciences
5AM Ventures
Boundless Bio
DCVC Bio
Radionetics Oncology
Careers
join us
News
Umesh Gangadharmath, Ph.D
Umesh Gangadharmath, Ph.D is Senior Vice President, Technical Operations and has focused his career on radiopharmaceutical development and manufacturing in both academic and commercial settings. He has over 16 years of experience in researching and developing novel radiopharmaceuticals in the areas of oncology, cardiology and neurology for use in positron emission tomography (PET) imaging and has established GMP radiopharmaceutical manufacturing sites globally to support clinical trials. Dr. Gangadharmath’s breadth of expertise spans from preclinical development, support of CMC sections for IND submissions, early clinical research, through full clinical production. Most recently, he was Chief Operating Officer at Optimal Tracers, a CDMO with the responsibility of supporting radiopharmaceutical production for biopharmaceutical companies. He spent the last 10 years building Optimal Tracers from concept to a mature, fully functioning GMP radiopharmaceutical manufacturing facility. Dr. Gangadharmath and his team at Optimal Tracers were also involved in establishing a fully GMP radiopharmaceutical manufacturing facility for clinical research at University Hospitals Cleveland Medical Center. Dr. Gangadharmath has held previous roles as Director for the biomedical cyclotron facility at UCLA and as Senior Scientist, Radiochemistry at Siemens Molecular Imaging Biomarker Research. He was part of the team that invented TAUVID during his work at Siemens Molecular Imaging Biomarker Research (Flortaucipir; Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company) for imaging tau pathology and is well-published in the field of radiopharmaceuticals. He also has served as a member of United States Pharmacopeia (USP) Radioactive Drugs Expert Panel and played a key role in setting up a molecular imaging program at Loma Linda University Medical Center. He received his M.Sc. and Ph.D in Inorganic Chemistry from Karnatak University Dharwad, India and completed a postdoctoral fellowship at UCLA under the supervision of Dr. Hartmuth Kolb.